MedTrace Logo

Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS

NCT03561922 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-04-19

No results posted yet for this study

Summary

This study aims to assess the impact of the subretinal implant RETINA IMPLANT Alpha AMS on the patient's daily life, using validated activities of daily living and questionnaires.

Conditions

  • Retinal Degeneration
  • Inherited Retinal Dystrophy Primarily Involving Sensory Retina

Interventions

DEVICE

RETINA IMPLANT Alpha AMS

Implantation of the subretinal RETINA IMPLANT Alpha AMS

Sponsors & Collaborators

  • Retina Implant AG

    lead INDUSTRY

Principal Investigators

  • Nicolas Leveziel, Prof · Centre Hospitalier Universitaire (CHU) de Poitiers, France

  • Pierre-André Duval, Dr · Clinique Saint Jean, Montpellier, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-04
Primary Completion
2019-04-05
Completion
2019-04-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03561922 on ClinicalTrials.gov